Assembly Biosciences, Inc.
Assembly Biosciences, Inc. (Nasdaq: ASMB) is a biotechnology company developing investigational therapies for serious viral diseases. Its pipeline includes clinical-stage candidates targeting recurrent genital herpes, hepatitis delta virus (HDV) and hepatitis B virus (HBV), along with an oral broad-spectrum candidate… From the company’s description.
Over the twelve months to Jun 30, 2026, Assembly Biosciences, Inc. reported revenue of $74.84M, up 125.1% from a year earlier, and a net loss of $0.04M. Its operating margin was −11.8%, and operations used $38.48M in cash. In fiscal 2025, it reported revenue of $72.30M, up 153.5% from fiscal 2024, and a net loss of $6.12M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Assembly Biosciences, Inc. does
In the company’s own words
Assembly Biosciences, Inc. (Nasdaq: ASMB) is a biotechnology company developing investigational therapies for serious viral diseases. Its pipeline includes clinical-stage candidates targeting recurrent genital herpes, hepatitis delta virus (HDV) and hepatitis B virus (HBV), along with an oral broad-spectrum candidate for transplant-associated herpesviruses in regulatory filing-enabling studies and earlier research programs. The candidates include helicase-primase inhibitors ABI-5366 and ABI-1179, an HDV entry inhibitor, a next-generation HBV capsid assembly modulator, and a non-nucleoside polymerase inhibitor. Gilead Sciences exercised its option to license the herpes program in December 2025 and controls its further development; Assembly retains other programs, including the HBV candidate for which it is evaluating partners. Assembly’s collaboration with Gilead also provides options to license other programs. The company’s research and development organization focuses on discovering and advancing antiviral therapies, and it has no approved products. Its website is www.assemblybio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1426800
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Assembly Biosciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Assembly Biosciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Assembly Biosciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Assembly Biosciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Assembly Biosciences, Inc.'s last four quarterly filings that the numbers alone won't show?”